Preterm birth is the single biggest cause of neonatal mortality and morbidity in the UK, affecting over 52 000 babies (around 7.3% of live births) in England and Wales in 2012. 1 About 75% of women delivering preterm do so after preterm labour, 2 which is sometimes preceded by preterm prelabour membrane rupture. A "cause" for preterm labour is not always found, but it may be associated with infection. In other cases, preterm birth may result from elective delivery.
Babies born preterm have high rates of mortality, with the risk of mortality being inversely proportional to gestational age at birth. 3 Babies who survive have increased rates of disability.
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This article summarises the most recent recommendations on the prevention, diagnosis, and management of preterm labour from the National Institute for Health and Care Excellence (NICE). Information and support for women having a planned preterm birth or who are offered treatment for preterm labour (and their family members or carers as appropriate)
• Provide information about the likelihood of the baby surviving and other outcomes (including long term outcomes) and risks for the baby, giving values as natural frequencies (such as 1 in 100).
• Explain about the neonatal care of preterm babies, including location of care.
• Explain about the immediate problems that can arise when a baby is born preterm.
[ • To diagnose preterm labour -consider transvaginal ultrasound measurement of cervical length to determine likelihood of birth within 48 hours for women who are ≥30 +0 weeks pregnant and are in suspected preterm labour. If cervical length is >15 mm, explain that she is unlikely to be in preterm labour.
• To treat preterm labour -offer tocolysis, corticosteroids, or magnesium sulfate to women in preterm labour, including those with a cervical length of <15 mm, depending on gestation and clinical circumstances.
What's new in this guidance
• Do not use diagnostic tests for preterm labour for symptomatic women who are <30 +0 weeks pregnant, but treat them as appropriate
• Use cervical length ultrasound for diagnosis of preterm labour for women at ≥30 +0 weeks of pregnancy and treat them as if they are in preterm labour if cervical length is found at ≤15 mm • Use prophylactic progesterone or cervical cerclage to prevent preterm birth to women with a history of spontaneous preterm birth or mid-trimester loss and cervical ultrasound measurement of <25 mm at 16 +0 to 24 +0 weeks gestation 
Rescue cerclage
• Do not offer "rescue" cervical cerclage to women with signs of infection, active vaginal bleeding, or uterine contractions.
• Consider rescue cervical cerclage for women between 16 +0 and 27 +6 weeks of pregnancy with a dilated cervix and exposed, unruptured fetal membranes.
[Based on low to very low quality evidence from randomised controlled trials and the experience and opinion of the GDG]

Fetal monitoring options (cardiotocography and intermittent auscultation)
• For women in preterm labour, discuss -the purpose of fetal monitoring and what it involves -the clinical decisions it informs at different gestational ages -if appropriate, the option not to monitor the fetal heart rate (for example, at the threshold of viability).
[Based on the experience and opinion of the GDG]
• Offer women in established preterm labour but with no other risk factors a choice of fetal heart rate monitoring using either -cardiotocography using external ultrasound or -intermittent auscultation.
[Based on moderate to very low quality evidence from randomised controlled trials and the experience and opinion of the GDG]
Mode of birth for women likely to deliver preterm (suspected, diagnosed, or established preterm labour)
• Discuss the general benefits and risks of caesarean section and vaginal birth with women likely to deliver preterm.
[Based on the experience and opinion of the GDG]
• Explain the benefits and risks of caesarean section that are specific to gestational age. 
Overcoming barriers
This guideline recommends strategies to reduce risks in women who are at high likelihood of preterm delivery. One of the main barriers to the implementation of this guidance is the availability of transvaginal ultrasound scans to diagnose preterm labour, and thus facilitate treatment and transfer to a place where appropriate neonatal intensive care can be provided, a strategy known to improve rates of survival for the baby. There is also currently variation in clinical practice in use of tocolytic agents, uncertainty as to which women will benefit, when it should be given, and the choice of tocolytic. The appropriate use of tocolysis will delay preterm delivery and allow additional antenatal strategies to improve outcomes for babies born preterm. Contributors: All authors contributed to the initial draft, helped revise the manuscript, and approved the final version for publication. GS is guarantor.
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How patients were involved in the creation of this article'
Committee members involved in this guideline included three lay members, who contributed to the formulation of the recommendations summarised here.
Further information on the guidance
This guideline was commissioned with the aim to standardise the care of women in preterm labour and address the knowledge gap regarding the management of preterm labour.
Guidelines into practice
• Audit the requests for diagnostic tests for preterm labour in women presenting with symptoms of preterm labour at ≥30 weeks of pregnancy. Do you need to change your practice by instead treating all symptomatic women who are pregnant <30 weeks as they were diagnosed for preterm labour?
• Audit the prescription of antibiotics for women with preterm prelabour rupture of membranes. Were all women offered antibiotic prophylaxis (erythromycin 250 mg four times a day for a maximum of 10 days)?
• Audit the use of magnesium sulfate for women who are pregnant ≤24 weeks. 
Methods
This guidance was developed by the National Collaborating Centre for Women's and Children's Health in accordance with NICE guideline development methods (www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf). A Guideline Development Group was established by the National Collaborating Centre for Women's and Children's Health, which incorporated healthcare professionals (including obstetricians and gynaecologists, midwives, neonatal nurses, and neonatologists) and lay members. The GDG identified relevant clinical questions, collected and appraised clinical evidence, and evaluated the cost effectiveness of proposed interventions where possible. A network meta-analysis was undertaken to identify the clinical effectiveness of different types of treatments for tocolysis which fitted the cost effectiveness analysis.
The draft guideline underwent a public consultation in which stakeholder organisations were invited to comment; the GDG then took all comments into consideration when producing the final version of the guideline.
Four different versions of this guideline have been produced: a full version containing all the evidence, the process undertaken to develop the recommendations, and all the recommendations; a care pathway; a version containing a list of all the recommendations, known as the "Short guideline"; and a version for the public. All of these versions are available from the NICE website (www.nice.org.uk/guidance/ng25).
Updates of the guideline will be produced as part of NICE's guideline development programme.
Future research
